Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ECG +16.7%, NUTX +10.6%, ABSI +8.8% (also announces first participants dosed in Phase 1 trial of ABS-101), ATXS +7.4%, EXEL +5%, SONY +4.8%, KRMN +4.6%, DT +3.2%, LUXE +3.1%, SFL +2.5%, ETON +1.5%
Other news:
- SMCI +15.8% (DataVolt announces landmark deal with Supermicro (SMCI) to accelerate adoption of rack-scale total liquid cooling IT solutions for future-ready AI data centers)
- FSP +5.5% (announces review of strategic alternatives)
- DRUG +4.4% (reportsfindings from its DBA/2 mouse model study, BMB-101)
- SGC +3.4% (files for $120 mln mixed shelf offering; also files for offering by selling shareholders)
- OABI +2.9% (showcases single B-cell screening platform)
- AEVA +2.8% (strategic collaboration with the technology focused affiliate of a Global Fortune 500 company to collaborate on bringing Aeva's next generation 4D LiDAR into new industrial and consumer markets)
- PSN +2.6% (awarded two contracts by King Salman Airport)
- BCRX +1.9% (FDA acceptance of NDA for ORLADEYO oral granules in patients with hereditary angioedema aged 2 to 11 years)
- GSK +1.5% (acquires efimosfermin from Boston Pharmaceuticals for $1.2 bln upfront)
- ACDC +1.2% (Executive Chairman bought 90,044 shares of Class A common stock worth approximately $426K)
- FRST +1.1% (to delay 10-Q filing)
- TEM +1% (six posters accepted for presentation)
- PBA +1% (announces renewal of share repurchase program)
- TBI +0.9% (adopts limited duration shareholder rights agreement)